SereNeuro Therapeutics revealed promising results for SN101, a first-in-class iPSC-derived therapy designed to treat chronic ...

SereNeuro Therapeutics, a preclinical biotechnology company developing non-opioid pain therapies, unveiled new data today on ...

SereNeuro Therapeutics, a preclinical biotechnology company developing non-opioid pain therapies, has unveiled new data on a ...

Scalable iPSC neuron manufacturing advances neuroscience, improving disease modeling, therapeutic development, and clinical readiness.

Yamagami, and Amaris Castañon will discuss the latest advances and innovations in neuroscience disease cell models.

SereNeuro Therapeutics, a preclinical biotechnology company developing non-opioid pain therapies, unveiled new data today on ...

A research team has made a stem cell medium that doesn't contain any human components. E. coli was used to introduce canine ...

Canine induced pluripotent stem (iPS) cells possess the ability to differentiate into any type of cell, making them a useful ...